Haivision Systems reports FQ4 results

[ad_1] Nemes Laszlo/iStock via Getty Images OS Therapies (NYSE:OSTX) is up ~65% in premarket trading Wednesday after releasing phase 2b data on OST-HER2 for prevention of recurrent, fully resected, lung metastatic osteosarcoma. Results indicated that the candidate met its primary endpoint of 12-month event-free survival. OST-HER2 had [ad_2]

[ad_1] Dec. 31, 2024 8:30 PM ETUnited States Oil Fund, LP ETF (USO), XLEUCO, FCEL, YPF, DBO, SUNE, USL, USLM, SCO, ALTM, BNO, SEDG, GUSH, DRIP, AQMS, VST, SEI, USOI, PLL, ASTI, NOVA, CO1:COM, HO1:COM, XB1:COM, CL1:COM, MAXN, EOSE, SMR, PPTA, WAVE, ASPI, ATLX, TLNBy: Carl Surran, SA News Editor SlavkoSereda/iStock via Getty Images Crude…